FADS2
Basic information
Region (hg38): 11:61792980-61867354
Previous symbols: [ "LLCDL2" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the FADS2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 6 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 5 | |||||
Total | 0 | 0 | 8 | 2 | 2 |
Variants in FADS2
This is a list of pathogenic ClinVar variants found in the FADS2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-61795501-G-A | not specified | Uncertain significance (Oct 05, 2022) | ||
11-61795593-G-A | not specified | Uncertain significance (Feb 16, 2023) | ||
11-61795654-C-T | not specified | Uncertain significance (Mar 17, 2023) | ||
11-61795672-G-A | Hereditary breast ovarian cancer syndrome | Uncertain significance (Aug 01, 2020) | ||
11-61795747-G-A | not specified | Uncertain significance (Jan 24, 2024) | ||
11-61795930-T-C | Uncertain significance (Apr 08, 2021) | |||
11-61796034-G-T | not specified | Uncertain significance (Jun 03, 2024) | ||
11-61796065-G-A | Non-immune hydrops fetalis | Uncertain significance (Apr 29, 2021) | ||
11-61796077-G-A | not specified | Uncertain significance (Mar 11, 2024) | ||
11-61796217-C-G | not specified | Uncertain significance (Jun 16, 2024) | ||
11-61796257-G-A | not specified | Uncertain significance (Apr 18, 2023) | ||
11-61796308-T-A | not specified | Uncertain significance (Sep 07, 2022) | ||
11-61796325-C-T | not specified | Uncertain significance (Mar 22, 2022) | ||
11-61796356-G-A | not specified | Uncertain significance (Nov 13, 2023) | ||
11-61796403-G-A | not specified | Uncertain significance (Feb 28, 2024) | ||
11-61796463-G-A | not specified | Uncertain significance (Apr 07, 2023) | ||
11-61802839-C-A | not specified | Uncertain significance (Sep 06, 2022) | ||
11-61803420-C-A | not specified | Uncertain significance (Mar 19, 2024) | ||
11-61812491-C-A | not specified | Uncertain significance (Aug 02, 2021) | ||
11-61812622-C-T | not specified | Likely benign (Jan 31, 2022) | ||
11-61812623-G-A | not specified | Uncertain significance (Aug 15, 2023) | ||
11-61816744-C-A | Likely benign (Jul 26, 2018) | |||
11-61816789-A-C | Likely benign (Jun 01, 2020) | |||
11-61816814-G-C | not specified | Uncertain significance (May 11, 2022) | ||
11-61816847-C-T | not specified | Uncertain significance (Jan 03, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
FADS2 | protein_coding | protein_coding | ENST00000278840 | 12 | 74375 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.998 | 0.00185 | 125744 | 0 | 3 | 125747 | 0.0000119 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.19 | 118 | 264 | 0.447 | 0.0000150 | 2974 |
Missense in Polyphen | 9 | 57.676 | 0.15604 | 705 | ||
Synonymous | 0.641 | 103 | 112 | 0.923 | 0.00000727 | 804 |
Loss of Function | 4.48 | 2 | 27.2 | 0.0735 | 0.00000127 | 280 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000901 | 0.00000879 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.0000375 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Component of a lipid metabolic pathway that catalyzes biosynthesis of highly unsaturated fatty acids (HUFA) from precursor essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3). Catalyzes the first and rate limiting step in this pathway which is the desaturation of LA (18:2n-6) and ALA (18:3n-3) into gamma- linoleic acid (GLA) (18:3n-6) and stearidonic acid (18:4n-3) respectively and other desaturation steps. Highly unsaturated fatty acids (HUFA) play pivotal roles in many biological functions. It catalizes as well the introduction of a cis double bond in palmitate to produce the mono-unsaturated fatty acid sapienate, the most abundant fatty acid in sebum. {ECO:0000269|PubMed:12713571, ECO:0000269|PubMed:9867867}.;
- Pathway
- Biosynthesis of unsaturated fatty acids - Homo sapiens (human);alpha-Linolenic acid metabolism - Homo sapiens (human);PPAR signaling pathway - Homo sapiens (human);Alpha Linolenic Acid and Linoleic Acid Metabolism;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;PPAR signaling pathway;Metabolism of lipids;alpha-linolenic acid (ALA) metabolism;Linoleic acid (LA) metabolism;alpha-linolenic (omega3) and linoleic (omega6) acid metabolism;Omega-3 fatty acid metabolism;Metabolism;Fatty acid metabolism;γ-linolenate biosynthesis;Linoleate metabolism;Omega-6 fatty acid metabolism;icosapentaenoate biosynthesis II (metazoa);docosahexaenoate biosynthesis III (mammals)
(Consensus)
Recessive Scores
- pRec
- 0.278
Intolerance Scores
- loftool
- 0.277
- rvis_EVS
- -0.38
- rvis_percentile_EVS
- 27.42
Haploinsufficiency Scores
- pHI
- 0.130
- hipred
- Y
- hipred_score
- 0.631
- ghis
- 0.574
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.992
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Fads2
- Phenotype
- digestive/alimentary phenotype; immune system phenotype; renal/urinary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; hematopoietic system phenotype; endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype;
Gene ontology
- Biological process
- unsaturated fatty acid biosynthetic process;alpha-linolenic acid metabolic process;linoleic acid metabolic process;oxidation-reduction process
- Cellular component
- endoplasmic reticulum membrane;integral component of plasma membrane;membrane
- Molecular function
- stearoyl-CoA 9-desaturase activity;linoleoyl-CoA desaturase activity